RE:RE:Discussions Involve Multiple Partners in Varying FormatsGeneral,
Your comment about SGLT2s got me wondering about DPP4s. From RVX's Jan 13 NR:
"When apabetalone was applied to top standard of care in diabetes patients their risk of MACE events was greatly reduced. In total, approximately 25% of BETonMACE patients were on new oral anti-diabetic treatments that included SGLT2 and DPP4 inhibitors. In combination with apabetalone, primary MACE was reduced by 57% and by 63% when hospitalization for congestive heart failure was included."
That NR didn't differentiate effectiveness between SGLT2s and DPP4s, yet the presentation from September 10 said we were going to choose one SGLT2 and from what I can recall, that presentation only talked about synergy with SGLT2s.
Perhaps makers of DPP4s weren't interested in partnerships? Seems strange unless there was a noticeable difference in syngery.
Did a quick scan for sales fiigures for some SGLT2s. Jardiance did 2.41 billion in sales last year.. The market for these drugs is simply too large for BP to not want in with the data we have,